SPDR S&P Health Equip

First Eagle Investment Management Acquires Envista Shares

DENTSPLY SIRONA Inc. Director Buys Shares

Dentsply Sirona director James D. Forbes purchases 5,000 company shares

Masimo released FY2025 earnings on February 27 After-Market EST, actual revenue USD 1.527 B (forecast USD 1.522 B), actual EPS USD -2.7973 (forecast USD 3.9983)

Masimo released FY2025 Q4 earnings on February 27 After-Market (EST), actual revenue USD 412.5 M (forecast USD 408.33 M), actual EPS USD 1.2891 (forecast USD 1.29)

DENTSPLY SIRONA updates 2026 fiscal year earnings guidance

Dentsply Sirona Misses Q4 Earnings Estimate

Dentsply Sirona Reports Earnings and Announces Restructuring Plan

Dentsply Sirona expects net sales of $3.5 billion to $3.6 billion for fiscal year 2023

Dentsply Sirona released FY2025 Q4 earnings on February 26 During-Market EST, actual revenue USD 961 M (forecast USD 926.37 M), actual EPS USD -0.7314 (forecast USD 0.0188)

Dentsply Sirona released FY2025 annual earnings on February 26 During-Market (EST), actual revenue USD 3.68 B (forecast USD 3.645 B), actual EPS USD -3 (forecast USD -2.2119)

Lantheus released FY2025 earnings on February 26 Pre-Market (EST), actual revenue USD 1.542 B (forecast USD 1.502 B), actual EPS USD 3.41 (forecast USD 3.1487)

Lantheus released FY2025 Q4 earnings on February 26 Pre-Market (EST), actual revenue USD 406.79 M (forecast USD 367.03 M), actual EPS USD 0.8126 (forecast USD 0.6675)

Lemaitre Vascular released FY2025 Q4 earnings on February 25 After-Market (EST), actual revenue USD 64.45 M (forecast USD 62.82 M), actual EPS USD 0.6799 (forecast USD 0.6636)

Lemaitre Vascular released FY2025 earnings on February 25 After-Market EST, actual revenue USD 249.6 M (forecast USD 247.99 M), actual EPS USD 2.52 (forecast USD 2.4654)

Leemet Medical Tubing Reports Q4 Financial Figures

Align Technology Launches iTero Lumina™ Pro Intraoral Scanner

Integer Holdings Receives Mixed Analyst Ratings, Target Price Increased

Tandem Diabetes released FY2025 Q4 earnings on February 19 After-Market (EST), actual revenue USD 290.38 M (forecast USD 277.24 M), actual EPS USD -0.0086 (forecast USD -0.0641)

Tandem Diabetes released FY2025 earnings on February 19 After-Market EST, actual revenue USD 1.015 B (forecast USD 1.001 B), actual EPS USD -3.0424 (forecast USD -2.8515)

Peraso

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

Decent

Edesa Biotech

Cre8 Enterprise - CL

AN2 Therapeutics

Day One Biopharmaceuticals

Epsium Enterprise

Silynxcom

Aptera Motors - B

A class action lawsuit has been filed against Boston Scientific Corporation, alleging violations of federal securities laws. The lawsuit seeks damages for investors who acquired the company's securities between July 23, 2025, and February 3, 2026, claiming the company made misleading statements about its projected growth in the U.S. electrophysiology segment. Investors have until May 4, 2026, to apply as lead plaintiff.

PUBT

Boston Scientific

iShares US Medical Devices

Class Action Lawsuit Targets Boston Scientific Over Alleged Investor Harm

SBIO

Agilent Technologies reported a 5.2% decline in stock price after raising its 2026 revenue guidance to $7.30-$7.50 billion, despite first-quarter earnings being slightly lower than the previous year. The company issued second-quarter revenue guidance of $1,790-$1,820 million, reflecting confidence in demand and cost control. However, ongoing tariff and supply chain pressures pose risks to margins. Analysts project a fair value range for the stock between $125.16 and $169.67, indicating differing views on growth versus risks. Investors are advised to consider these factors in their investment decisions.

Simplywall

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Agilent Tech

iShares Biotechnology ETF

Agilent Technologies (A) Is Down 5.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?

Becton, Dickinson (NYSE: BDX) and Medtronic (NYSE: MDT) are highlighted as top dividend stocks under $1,000. Becton, Dickinson boasts a 50-year dividend increase history and a yield of 2.4%, while Medtronic, nearing Dividend King status, offers a 2.9% yield and growth potential from its new surgical robots. Both companies are positioned for growth despite recent challenges, making them attractive options for dividend investors looking to enhance their healthcare portfolios.

nasdaq

Medtronic

Becton Dickinson and

2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000

IRIX

Idorsia (SWX:IDIA) Valuation Check After Recent Share Price Weakness And Pipeline Expectations

Iridex

Idorsia (SWX:IDIA) Valuation Check After Recent Share Price Weakness And Pipeline Expectations

INSP

Regal Partners Ltd has acquired a new position in Inspire Medical Systems, Inc. (NYSE:INSP), purchasing 101,714 shares valued at approximately $7.5 million, making it the 26th largest position in their portfolio. Other institutional investors have also increased their stakes in Inspire Medical Systems. The company's stock opened at $63.01, with a market cap of $1.80 billion and a PE ratio of 12.65. Analysts have mixed ratings on the stock, with an average rating of "Hold" and a consensus price target of $104.24.

Market Beat

Inspire Medical

Regal Partners Ltd Buys New Holdings in Inspire Medical Systems, Inc. $INSP

Modern Wealth Management LLC increased its stake in Johnson & Johnson (NYSE: JNJ) by 10.8% in Q3, now holding 44,105 shares valued at $8.18 million. Other institutional investors, including Vanguard and Geode Capital, also raised their stakes. Johnson & Johnson's stock opened at $240.57, with a market cap of $579.75 billion and a PE ratio of 21.77. The company declared a quarterly dividend of $1.30 per share, with a yield of 2.2%. Analysts have set target prices ranging from $220 to $255, with a consensus rating of "Moderate Buy."

iShares Global Healthcare

VG Health

Johnson & Johnson

iShares US Pharma

Health Care Select Sector SPDR

Modern Wealth Management LLC Increases Stock Position in Johnson & Johnson $JNJ

Orion Portfolio Solutions LLC increased its stake in Boston Scientific Corporation (NYSE:BSX) by 60% in Q3, owning 58,486 shares valued at $5.71 million. Other investors also adjusted their positions, with 89.07% of the stock held by institutional investors. Boston Scientific's stock opened at $71.24, with a market cap of $105.71 billion. The company reported Q4 earnings of $0.80 per share, exceeding estimates, and set guidance for Q1 2026 at 0.780-0.800 EPS. CEO Michael F. Mahoney sold 160,901 shares, reducing his ownership by 10.23%.

Orion Porfolio Solutions LLC Boosts Position in Boston Scientific Corporation $BSX

IFG Advisory LLC has reduced its stake in Medtronic PLC by 76% during Q3, selling 28,471 shares and retaining 8,996 shares valued at $857,000. Other institutional investors have also made changes to their positions in Medtronic. Additionally, EVP Harry Skip Kiil sold 52,524 shares, decreasing his position by 61.58%. Analysts have upgraded Medtronic's rating, with a current average target price of $110.74. The company has announced a quarterly cash dividend of $0.71 per share and made progress in diabetes care with the launch of the MiniMed Go Smart MDI system in Europe.

IFG Advisory LLC Sells 28,471 Shares of Medtronic PLC $MDT

TMDX

TransMedics Group's stock has surged 104% over the past year, establishing itself as a leader in the organ transplant industry with a 20% market share in the U.S. Despite being labeled "overvalued," the company continues to outperform expectations. Its innovative Organ Care System (OCS) enhances organ preservation and utilization rates, while its logistics network supports efficient organ transport. The founder-led company has shown strong price appreciation since its IPO, although it faces scrutiny over management ratings and high short interest. Investors are encouraged to consider its growth potential despite valuation concerns.

TransMedics

TransMedics Stock Is Up 104% Over the Last Year: Is It Too Late to Buy for 2026?

Grantham Mayo Van Otterloo & Co. LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 15.7% in Q3, now holding 2,141,863 shares, making it the 9th largest position in their portfolio. The firm owns about 0.57% of Thermo Fisher, valued at approximately $1.04 billion. Other institutional investors, including Vanguard and Norges Bank, have also adjusted their holdings. Analysts have set a consensus price target of $633.68 for the stock, which opened at $501.72, with a market cap of $186.38 billion and a recent EPS of $6.57, exceeding estimates.

Thermo Fisher Scentific

Thermo Fisher Scientific Inc. $TMO is Grantham Mayo Van Otterloo & Co. LLC's 9th Largest Position

ARKG

Grantham Mayo Van Otterloo & Co. LLC increased its stake in Abbott Laboratories (NYSE:ABT) by 4.6% in Q3, now holding 8,176,484 shares valued at approximately $1.1 billion. The stock represents 3.1% of their portfolio. Other institutional investors also adjusted their holdings. Abbott's stock recently opened at $109.74, down 1.2%, with a market cap of $190.69 billion. The company announced a quarterly dividend of $0.63 per share, with a yield of 2.3%. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy."

Abbott Laboratories

Ark Genomic Revolution ETF

Abbott Laboratories $ABT Position Raised by Grantham Mayo Van Otterloo & Co. LLC

UFPT

UFP Technologies (UFPT) reported strong Q4 earnings, highlighting a 19.5% revenue increase to $602.8 million for fiscal 2025, nearly tripling since 2021. Despite labor inefficiencies and a cyber incident, management remains optimistic about long-term growth, citing a 435% rise in operating income since 2021. Adjusted operating margins held at 17.1%, and cash flow supported capital spending and debt reduction. Major contract extensions and new program launches signal continued expansion, while labor issues and a ransomware attack posed near-term challenges. Overall, the company is positioned for sustained growth in the medtech sector.

Tip Ranks

UFP Tech

UFP Technologies Signals Growth Momentum Despite Headwinds

SGHT

Sight Sciences Earnings Call Highlights Disciplined Growth

Sight Sciences

Sight Sciences Earnings Call Highlights Disciplined Growth

Maxim Group has maintained its Buy rating for Daxor (DXR) and set a price target of $22.00, while the stock closed at $11.38. The overall analyst consensus for Daxor is a Moderate Buy with an average price target of $23.00, indicating a potential upside of 102.20%. Lake Street also reiterated a Buy rating with the same price target of $23.00 in a report from March 5.

Daxor

Maxim Group Sticks to Its Buy Rating for Daxor (DXR)

LABD

At the CRT annual conference, Dr. Christopher Chieh Yang Koo presented the first US Medicare outcomes data for angiography-derived physiology (ADP) from over 4,000 CathWorks FFRangio patients. The study shows that ADP demonstrates similar clinical outcomes to invasive pressure wire-guided PCI through two years, with a comparable cumulative incidence of major adverse cardiac events (MACE). The adoption of ADP has grown significantly, and experts believe it may become the new standard of care for physiology in cardiovascular disease diagnosis and treatment.

prnewswire

Direxion S&P Biotech Bear 3X

16:00 ETLate-Breaking Clinical Trial Presentation of the First-Ever US Cohort of Over 4,000 CathWorks FFRangio Patients Demonstrates Similar Clinical Outcomes to Invasive Pressure Wire-Guided PCI through 2 Years

SPDR S&P Health Equip(XHE.US)

Class Action Lawsuit Targets Boston Scientific Over Alleged Investor Harm

Agilent Technologies (A) Is Down 5.2% After Raising 2026 Revenue Guidance – Has The Bull Case Changed?

2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000

Idorsia (SWX:IDIA) Valuation Check After Recent Share Price Weakness And Pipeline Expectations

Regal Partners Ltd Buys New Holdings in Inspire Medical Systems, Inc. $INSP